» » »

Flu Vaccine for Seniors Approved Boston MA

Seniors are at highest risk for complications of seasonal flu, including hospitalization and death. The Fluzone High-Dose vaccine, designed to prevent infection with influenza subtypes A and B, was given accelerated approval as a product designed to prevent serious or life-threatening disease.

Diane E Krause, MD
(617) 636-3271
260 Tremont St
Boston, MA
Business
New England Medical Center Internal Medicine
Specialties
Internal Medicine

Data Provided by:
James W May Jr. MD
(617) 726-8220
15 Parkman St, STE 435
Boston, MA
Specialties
Cosmetic Surgery

Data Provided by:
Boston Copley Square Chiropractic - Boston
(617) 206-9933
304 Columbus Ave
Boston, MA

Data Provided by:
Robert Oates, MD
(617) 638-8485
720 Harrison Ave
Boston, MA
Business
Boston University Medical Center Urologists
Specialties
Urology

Data Provided by:
Arthur L Day, MD
(617) 732-6810
45 Francis St
Boston, MA
Business
Brigham & Women's Hospital Neurosurgery
Specialties
Neurology

Data Provided by:
Brian J Awbrey MD
(617) 726-3808
151 Merrimac St
Boston, MA
Specialties
Orthopedics

Data Provided by:
Diamond Chiropractic
(617) 262-2225
224 Clarendon Street
Boston, MA

Data Provided by:
Recreation Chiropractic
(617) 678-7888
224 Clarendon Street Suite 32
Boston, MA

Data Provided by:
Lawrence Ira Karlin, MD
(617) 355-6021
300 Longwood Ave
Boston, MA
Business
Children's Hospital Boston Orthopaedic Surger
Specialties
Orthopedics

Data Provided by:
Ajay D Wasan, MD
(617) 732-8510
75 Francis St
Boston, MA
Business
Brigham & Women's Hospital Anesthesiology
Specialties
Anesthesiology

Data Provided by:
Data Provided by:

Flu Vaccine for Seniors Approved

Provided By:

THURSDAY, Dec. 24 (HealthDay News) -- Fluzone High-Dose, a seasonal flu vaccine for people 65 and older, has been approved by the U.S. Food and Drug Administration, the agency said in a news release.

Seniors are at highest risk for complications of seasonal flu, including hospitalization and death. The Fluzone High-Dose vaccine, designed to prevent infection with influenza subtypes A and B, was given accelerated approval as a product designed to prevent serious or life-threatening disease. As part of the approval, manufacturer Sanofi Pasteur is required to "conduct further studies to verify that [the vaccine] will decrease seasonal influenza after vaccination," the FDA said.

Because of the vaccine's higher potency, mild side effects were reported more frequently compared with Sanofi's standard-strength Fluzone vaccine, the agency said. These included pain, injection-site redness and swelling, headache, muscle ache and fever.

People who are sensitive to egg products or who have had life-threatening reactions to prior flu shots shouldn't be vaccinated with Fluzone High-Dose, the FDA said.

More information

The U.S. Centers for Disease Control and Prevention has more about flu vaccination.

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com